Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 20Unknown 8Recruiting 4Terminated 1Not yet recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Classical hematology 1

Conditions

Venous Thromboembolism 1Neoplasms 1

Interventions

Cyclophosphamide 390Carboplatin 344Gemcitabine 332pembrolizumab 329Cisplatin 328Paclitaxel 297Radiotherapy 296Docetaxel 286Bevacizumab 253Rituximab 234Capecitabine 223Nivolumab 220Dexamethasone 206Fluorouracil 190fludarabine 177Oxaliplatin 177Pemetrexed 153Doxorubicin 153Irinotecan 148Leucovorin 144Etoposide 144Cytarabine 133Cetuximab 129Bortezomib 129fludarabine phosphate 128Lenalidomide 126Erlotinib Hydrochloride 120Filgrastim 119Temozolomide 113Radiosurgery 113

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Rivaroxaban × Clear all
NCT02583191 2021-05-03

Rivaroxaban in the Treatment of Venous Thromboembolism (VTE) in Cancer Patients

AIO-Studien-gGmbH

Phase 3 Terminated
246 enrolled
Classical hematology

Neoplasms, Venous Thromboembolism

Data powered by HemOnc (CC BY 4.0) Colophon âš¡